FR3126870A1 - Pharmaceutical or cosmetic composition intended to improve cellulite and varicose veins, characterized in that it comprises a combination of theanine and polysaccharides derived from matcha. - Google Patents
Pharmaceutical or cosmetic composition intended to improve cellulite and varicose veins, characterized in that it comprises a combination of theanine and polysaccharides derived from matcha. Download PDFInfo
- Publication number
- FR3126870A1 FR3126870A1 FR2109754A FR2109754A FR3126870A1 FR 3126870 A1 FR3126870 A1 FR 3126870A1 FR 2109754 A FR2109754 A FR 2109754A FR 2109754 A FR2109754 A FR 2109754A FR 3126870 A1 FR3126870 A1 FR 3126870A1
- Authority
- FR
- France
- Prior art keywords
- pharmaceutical
- emulsion
- cosmetic composition
- skin
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 239000002537 cosmetic Substances 0.000 title claims abstract description 14
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 title claims abstract description 12
- 208000035484 Cellulite Diseases 0.000 title claims abstract description 11
- 206010049752 Peau d'orange Diseases 0.000 title claims abstract description 11
- 206010046996 Varicose vein Diseases 0.000 title claims abstract description 11
- 230000036232 cellulite Effects 0.000 title claims abstract description 11
- 208000027185 varicose disease Diseases 0.000 title claims abstract description 11
- 150000004676 glycans Chemical class 0.000 title claims abstract description 8
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 8
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 8
- 229940026510 theanine Drugs 0.000 title claims abstract description 6
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 9
- 239000002207 metabolite Substances 0.000 claims abstract description 8
- 235000006468 Thea sinensis Nutrition 0.000 claims abstract description 7
- 235000014469 Bacillus subtilis Nutrition 0.000 claims abstract description 5
- 244000052707 Camellia sinensis Species 0.000 claims abstract 3
- 239000000839 emulsion Substances 0.000 claims description 12
- 239000000499 gel Substances 0.000 claims description 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- DANYIYRPLHHOCZ-UHFFFAOYSA-N 5,7-dihydroxy-4'-methoxyflavone Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 DANYIYRPLHHOCZ-UHFFFAOYSA-N 0.000 claims description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 6
- 230000004089 microcirculation Effects 0.000 claims description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 6
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 claims description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 230000004151 fermentation Effects 0.000 claims description 5
- 238000000855 fermentation Methods 0.000 claims description 5
- 230000000968 intestinal effect Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- 230000000975 bioactive effect Effects 0.000 claims description 4
- 238000005187 foaming Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000012071 phase Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 230000008719 thickening Effects 0.000 claims description 4
- 210000000689 upper leg Anatomy 0.000 claims description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 3
- MXYUKLILVYORSK-UHFFFAOYSA-N (+/-)-allo-lobeline Natural products C1CCC(CC(=O)C=2C=CC=CC=2)N(C)C1CC(O)C1=CC=CC=C1 MXYUKLILVYORSK-UHFFFAOYSA-N 0.000 claims description 3
- MXYUKLILVYORSK-HBMCJLEFSA-N (-)-lobeline Chemical compound C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1 MXYUKLILVYORSK-HBMCJLEFSA-N 0.000 claims description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 3
- HGUVPEBGCAVWID-KETMJRJWSA-N 7-O-(beta-D-glucosyl)isovitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1O)[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 HGUVPEBGCAVWID-KETMJRJWSA-N 0.000 claims description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 claims description 3
- 235000009962 acacetin Nutrition 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 230000017531 blood circulation Effects 0.000 claims description 3
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000005487 catechin Nutrition 0.000 claims description 3
- 229950001002 cianidanol Drugs 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 229940074391 gallic acid Drugs 0.000 claims description 3
- 235000004515 gallic acid Nutrition 0.000 claims description 3
- 229960002339 lobeline Drugs 0.000 claims description 3
- 229930013610 lobeline Natural products 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 235000008160 pyridoxine Nutrition 0.000 claims description 3
- 239000011677 pyridoxine Substances 0.000 claims description 3
- 229930192014 saikosaponin Natural products 0.000 claims description 3
- HGUVPEBGCAVWID-UHFFFAOYSA-N saponarin Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)C2C(C(O)C(O)C(CO)O2)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 HGUVPEBGCAVWID-UHFFFAOYSA-N 0.000 claims description 3
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 claims description 3
- 229940011671 vitamin b6 Drugs 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 102000004882 Lipase Human genes 0.000 claims description 2
- 108090001060 Lipase Proteins 0.000 claims description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims description 2
- 238000009825 accumulation Methods 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000012867 bioactive agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 235000019197 fats Nutrition 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 210000002414 leg Anatomy 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000004530 micro-emulsion Substances 0.000 claims description 2
- 239000007908 nanoemulsion Substances 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000007762 w/o emulsion Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 241001037822 Bacillus bacterium Species 0.000 abstract 1
- 210000001789 adipocyte Anatomy 0.000 description 8
- 230000004075 alteration Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 244000269722 Thea sinensis Species 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 230000004130 lipolysis Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000004132 lipogenesis Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000027932 Collagen disease Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 102100029820 Mitochondrial brown fat uncoupling protein 1 Human genes 0.000 description 1
- 108050002686 Mitochondrial brown fat uncoupling protein 1 Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 description 1
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Medical Informatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Composition pharmaceutique ou cosmétique destinée à améliorer l’apparence de la cellulite et à diminuer les varices, caractérisée en ce qu’elle comprend une association de théanine et des polysaccharides extraits de Camellia sinensis, et d’au moins 2 métabolites produits par une bactérie Bacillus subtilis tel que Bacillus subtilis Gozen GZN-08 .Pharmaceutical or cosmetic composition intended to improve the appearance of cellulite and to reduce varicose veins, characterized in that it comprises a combination of theanine and polysaccharides extracted from Camellia sinensis, and at least 2 metabolites produced by a Bacillus bacterium subtilis such as Bacillus subtilis Gozen GZN-08.
Description
La présente invention a pour objet une composition pharmaceutique ou cosmétique destinée à améliorer l’apparence de la cellulite et à diminuer les varices caractérisée en ce que ladite composition comprend une association de théanine et des polysaccharides extraits des feuilles de matchaCamellia sinensis, et d’au moins 2 métabolites produits par la bactérieBacillus subtilis Gozen GZN-08parmi le groupe : acide gallique, lobéline, biotine, catéchine, pyridoxine, acide syringique, butyrate, propionate, zinc, acide linoléique, saikosaponine, acacétine, saponarine, acide butyrique.The subject of the present invention is a pharmaceutical or cosmetic composition intended to improve the appearance of cellulite and to reduce varicose veins, characterized in that the said composition comprises a combination of theanine and polysaccharides extracted from the leaves of matcha Camellia sinensis , and at least 2 metabolites produced by the bacterium Bacillus subtilis Gozen GZN-08 from the group: gallic acid, lobeline, biotin, catechin, pyridoxine, syringic acid, butyrate, propionate, zinc, linoleic acid, saikosaponin, acacetin, saponarin, butyric acid.
On sait que la cellulite est un problème esthétique appelé « lipodystrophie gynoïde (GLD) » touchant 85 à 98% des femmes post-pubertaires. La cellulite est une altération de la topographie de la peau qui survient au niveau de la région pelvienne, des membres inférieurs et de l'abdomen. Elle se caractérise par un aspect capitonné ou « peau d'orange ». C'est un problème complexe mettant en jeu le système micro circulatoire et lymphatique, ainsi que la matrice extracellulaire et la présence d'un excès de graisse sous‐cutanée dans le derme. En effet, il est caractérisé par une altération des adipocytes associée à une stase lymphatique, une diminution du flux sanguin et une augmentation de protéines dans le liquide interstitiel provoquant une altération de la microcirculation, une diminution de la collagenèse associée à une hyperkératose folliculaire qui provoque l’apparence de peau d’orange et une altération du tissu sous-cutané du derme profond donnant une texture granulaire à la peau. Certains facteurs prédisposent les femmes à une GLD : génétiques (sexe, race, distribution des tissus adipeux), hormonal (insuline, œstrogène, prolactine), vasculaire, mauvaise hygiène de vie (sédentarité, alimentation). Une altération de la microcirculation peut induire également des varices. Les varices sont une dilatation anormale d'une veine et sont visibles sous la peau au niveau des membres inférieurs de manière disgracieuse. Pour réduire la cellulite, c’est-à-dire diminuer les tensions générées sur les fibres conjonctives, il faut diminuer le volume des adipocytes, ce qui revient à diminuer leur contenu en triglycérides et donc stimuler la lipolyse ou réduire la lipogenèse. La lipogenèse est une voie métabolique qui permet d’estérifier les acides gras sous forme de triglycérides où ils seront stockés dans les adipocytes. Les triglycérides sont fabriqués dans le foie, dans les cellules adipeuses ainsi que dans les cellules intestinales. La lipolyse correspond au catabolisme des triglycérides stockés dans les adipocytes c’est-à-dire leur dégradation en acides gras non estérifiés et en glycérol. Les molécules ainsi libérées dans le flux sanguin peuvent être utilisées par d’autres tissus comme substrat énergétique (acides gras) ou servir de précurseurs néoglucogéniques (glycérol). Un des traitements actuels contre la cellulite utilise des essences de plantes (EP2813207) mais a besoin de plusieurs essences pour que cela fonctionne. Un autre traitement (W02011152692) utilisant un actif naturel, la fucoxanthine est utilisé contre la cellulite. Ce traitement permet d’activer l’expression UCP-1 dans la masse grasse blanche, ce qui provoque l’apoptose des cellules adipeuses donc une réduction de la cellulite. Cependant, il existe d’autres mécanismes permettant de réduire la taille des adipocytes comme une augmentation intracellulaire d’AMPc, une réduction de la lipogenèse ou une augmentation de la lipolyse. Ce traitement n’est donc efficace que partiellement dans l’augmentation de la lipolyse. De plus, il ne prend pas en compte la réduction des varices ou l’amélioration de la microcirculation.It is known that cellulite is an aesthetic problem called "gynoid lipodystrophy (GLD)" affecting 85 to 98% of post-pubertal women. Cellulite is an alteration in the topography of the skin that occurs in the pelvic region, lower limbs and abdomen. It is characterized by a padded or "orange peel" appearance. It is a complex problem involving the microcirculatory and lymphatic system, as well as the extracellular matrix and the presence of excess subcutaneous fat in the dermis. Indeed, it is characterized by an alteration of adipocytes associated with lymphatic stasis, a decrease in blood flow and an increase in proteins in the interstitial fluid causing an alteration in microcirculation, a decrease in collagenosis associated with follicular hyperkeratosis which causes the appearance of orange peel and an alteration of the subcutaneous tissue of the deep dermis giving a granular texture to the skin. Certain factors predispose women to GLD: genetic (sex, race, distribution of adipose tissue), hormonal (insulin, estrogen, prolactin), vascular, poor lifestyle (sedentary lifestyle, diet). An alteration of the microcirculation can also induce varicose veins. Varicose veins are an abnormal dilation of a vein and are visible under the skin in the lower limbs in an unsightly way. To reduce cellulite, i.e. to reduce the tensions generated on the connective fibers, it is necessary to reduce the volume of the adipocytes, which amounts to reducing their triglyceride content and therefore stimulating lipolysis or reducing lipogenesis. Lipogenesis is a metabolic pathway that allows fatty acids to be esterified in the form of triglycerides where they will be stored in adipocytes. Triglycerides are made in the liver, in fat cells and in intestinal cells. Lipolysis corresponds to the catabolism of triglycerides stored in adipocytes, i.e. their degradation into non-esterified fatty acids and glycerol. The molecules thus released into the blood stream can be used by other tissues as an energy substrate (fatty acids) or serve as neoglucogenic precursors (glycerol). One of the current cellulite treatments uses herbal essences (EP2813207) but needs multiple essences for it to work. Another treatment (W02011152692) using a natural active ingredient, fucoxanthin is used against cellulite. This treatment activates UCP-1 expression in the white fat mass, which causes apoptosis of fat cells and therefore a reduction in cellulite. However, there are other mechanisms that can reduce the size of adipocytes such as an intracellular increase in cAMP, a reduction in lipogenesis or an increase in lipolysis. This treatment is therefore only partially effective in increasing lipolysis. In addition, it does not take into account the reduction of varicose veins or the improvement of microcirculation.
C’est en étudiant les propriétés des métabolites du thé vert que la demanderesse a mis en évidence que les problèmes liés à une augmentation de la taille des adipocytes, une altération de la microcirculation ainsi que l’apparence des varices et une altération de la matrice extracellulaire peuvent être améliorés par un traitement composé de ces métabolites.It was by studying the properties of green tea metabolites that the applicant demonstrated that the problems linked to an increase in the size of adipocytes, an alteration of microcirculation as well as the appearance of varicose veins and an alteration of the matrix extracellular can be improved by a treatment composed of these metabolites.
Pour ce faire, la demanderesse a développé une composition pharmaceutique ou cosmétique destinée à être utilisée par voie topique ou orale comprenant une association de théanine et des polysaccharides extraits des feuilles de matchaCamellia sinensis, associée à au moins 2 métabolites, tyiquement produits par la bactérieBacillus subtilis Gozen GZN-08. Ces métabolites peuvent être préparés par la fermentation deBacillus subtilis Gozen GZN-08.To do this, the Applicant has developed a pharmaceutical or cosmetic composition intended for topical or oral use comprising a combination of theanine and polysaccharides extracted from Camellia sinensis matcha leaves, combined with at least 2 metabolites, typically produced by the bacterium Bacillus subtilis Gozen GZN-08 . These metabolites can be prepared by fermentation of Bacillus subtilis Gozen GZN-08 .
RESUMÉSUMMARY
Dans un premier aspect l’invention a trait à une composition pharmaceutique ou cosmétique destinée à améliorer l’apparence de la cellulite et à diminuer les varices caractérisée en ce qu’elle comprend une association de bioactifs comprenant de la théanine et des polysaccharides extraits des feuilles de matcha Camellia sinensis, et au moins 2 métabolites produits par une bactérie Bacillus subtilis choisis dans le groupe : acide gallique, lobéline, biotine, catéchine, pyridoxine, acide syringique, butyrate, propionate, zinc, acide linoléique, saikosaponine, acacétine, saponarine.In a first aspect, the invention relates to a pharmaceutical or cosmetic composition intended to improve the appearance of cellulite and to reduce varicose veins, characterized in that it comprises a combination of bioactive agents comprising theanine and polysaccharides extracted from the leaves matcha Camellia sinensis, and at least 2 metabolites produced by Bacillus subtilis bacteria selected from the group: gallic acid, lobeline, biotin, catechin, pyridoxine, syringic acid, butyrate, propionate, zinc, linoleic acid, saikosaponin, acacetin, saponarin.
Dans un mode de réalisation la composition pharmaceutique selon l’invention comprend du zinc à une concentration d’au moins 0,5% et de préférence d’au moins 2% en poids par rapport au poids total des bioactifs dans ladite composition et des polysaccharides à une concentration d’au moins 0,5% et de préférence d’au moins 5% en poids par rapport au poids total des bioactifs dans ladite composition.In one embodiment, the pharmaceutical composition according to the invention comprises zinc at a concentration of at least 0.5% and preferably at least 2% by weight relative to the total weight of the bioactives in said composition and of the polysaccharides at a concentration of at least 0.5% and preferably at least 5% by weight relative to the total weight of the bioactives in said composition.
Dans un deuxième aspect, l’invention porte sur un procédé de fabrication pour la réalisation de la composition pharmaceutique ou cosmétique selon l’invention. Le procédé comprend une étape de fermentation naturelle des feuilles de matchaCamellia sinensisà l’air libre, suivie d’une fermentation contrôlée en présence deBacillus subtilis ,typiquementBacillus subtilis Gozen GZN-08 ,à une température comprise entre 25 et 30°C.In a second aspect, the invention relates to a manufacturing process for producing the pharmaceutical or cosmetic composition according to the invention. The process includes a step of natural fermentation of Camellia sinensis matcha leaves in the open air, followed by controlled fermentation in the presence of Bacillus subtilis , typically Bacillus subtilis Gozen GZN-08 , at a temperature between 25 and 30°C .
L’invention se réfère également à une composition pharmaceutique ou cosmétique susceptible d’être obtenue par le procédé de l’invention.The invention also refers to a pharmaceutical or cosmetic composition capable of being obtained by the process of the invention.
La composition pharmaceutique ou cosmétique selon l’un quelconque aspects et modes de réalisation susmentionnés peut être sous la forme d’une émulsion huile dans eau (H/E) ou eau dans huile (E/H), d’émulsion multiple (H/E/H, E/H/E), de microémulsion, d’émulsion à phase gémellaires, d’émulsion PIT, de nano-émulsion, de pseudo-émulsion, de gel aqueux, de gel gras, de gel hydro-alcoolique, de phase grasse, de suspension, de savon liquide ou solide, de solution moussante ou non, de poudre, de gel ou d’émulsion lyophilisée, de préférence sous la forme de crèmes, liquides, pâtes, lotions, émulsions, huiles, gels, sirops, solides, poudres, masques, stick, comprimés, sprays, aérosol, gélules, ou de sirop.The pharmaceutical or cosmetic composition according to any of the aforementioned aspects and embodiments may be in the form of an oil-in-water (O/W) or water-in-oil (W/O) emulsion, of a multiple emulsion (O/ W/O, W/O/W), microemulsion, twin phase emulsion, PIT emulsion, nano-emulsion, pseudo-emulsion, aqueous gel, fatty gel, hydro-alcoholic gel, fatty phase, suspension, liquid or solid soap, foaming or non-foaming solution, powder, gel or freeze-dried emulsion, preferably in the form of creams, liquids, pastes, lotions, emulsions, oils, gels, syrups, solids, powders, masks, sticks, tablets, sprays, aerosol, capsules, or syrup.
Dans un troisième aspect, l’invention porte sur la composition pharmaceutique de l’invention, pour son utilisation dansIn a third aspect, the invention relates to the pharmaceutical composition of the invention, for its use in
- la réduction de l’accumulation de graisse dans le tissu adipeux et intestinal en inhibant l’enzyme intestinale lipase et l’enzyme phosphodiestérase ; et/ou- the reduction of fat accumulation in adipose and intestinal tissue by inhibiting the intestinal enzyme lipase and the enzyme phosphodiesterase; and or
- pour diminuer le risque d’apparition de varices, pour fluidifier la circulation sanguine et/ou pour et améliorer la micro-circulation dans les jambes.- to reduce the risk of appearance of varicose veins, to improve blood circulation and/or to improve micro-circulation in the legs.
Dans un quatrième aspect, l’invention porte sur l’utilisation non-thérapeutique d’une composition cosmétique selon l’invention pour tonifier la peau des cuisses et des bras, pour épaissir la peau des cuisses et des bras, pour moduler la production d’acide hyaluronique par les cellules de la peau, pour améliorer l’apparence de la peau et augmenter l’élasticité de la peau, ou pour moduler l’épaississement des fibres de collagène de la peau.In a fourth aspect, the invention relates to the non-therapeutic use of a cosmetic composition according to the invention for toning the skin of the thighs and arms, for thickening the skin of the thighs and arms, for modulating the production of hyaluronic acid by skin cells, to improve skin appearance and increase skin elasticity, or to modulate the thickening of skin collagen fibers.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2109754A FR3126870A1 (en) | 2021-09-16 | 2021-09-16 | Pharmaceutical or cosmetic composition intended to improve cellulite and varicose veins, characterized in that it comprises a combination of theanine and polysaccharides derived from matcha. |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2109754A FR3126870A1 (en) | 2021-09-16 | 2021-09-16 | Pharmaceutical or cosmetic composition intended to improve cellulite and varicose veins, characterized in that it comprises a combination of theanine and polysaccharides derived from matcha. |
| FR2109754 | 2021-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR3126870A1 true FR3126870A1 (en) | 2023-03-17 |
Family
ID=78649425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR2109754A Pending FR3126870A1 (en) | 2021-09-16 | 2021-09-16 | Pharmaceutical or cosmetic composition intended to improve cellulite and varicose veins, characterized in that it comprises a combination of theanine and polysaccharides derived from matcha. |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR3126870A1 (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040092538A (en) * | 2003-04-24 | 2004-11-04 | 주식회사 태평양 | Composition for external application to the skin containing the active ingredients of green tea |
| US20050106263A1 (en) * | 2003-11-19 | 2005-05-19 | Yucel Donmez | Green tea, multivitamin, mineral and herb based hair and male facial skin formulas |
| WO2011152692A2 (en) | 2010-06-03 | 2011-12-08 | 주식회사 리스토어랩스 | Anti-obesity cream composition containing fucoxanthin |
| KR20140103488A (en) * | 2013-02-18 | 2014-08-27 | 정읍시 | Fermented green tea using microorganism and method for preparing the same |
| EP2813207A1 (en) | 2013-05-24 | 2014-12-17 | Roberto Bianco | Anti-cellulite product based on natural essences |
| JP2020036561A (en) * | 2018-09-05 | 2020-03-12 | 株式会社 伊藤園 | Green tea composition for inhibition of reduction of cognitive function associated with workload |
| WO2020096299A1 (en) * | 2018-11-05 | 2020-05-14 | (주)아모레퍼시픽 | Green tea extract having modified constituent content and composition comprising same |
-
2021
- 2021-09-16 FR FR2109754A patent/FR3126870A1/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040092538A (en) * | 2003-04-24 | 2004-11-04 | 주식회사 태평양 | Composition for external application to the skin containing the active ingredients of green tea |
| US20050106263A1 (en) * | 2003-11-19 | 2005-05-19 | Yucel Donmez | Green tea, multivitamin, mineral and herb based hair and male facial skin formulas |
| WO2011152692A2 (en) | 2010-06-03 | 2011-12-08 | 주식회사 리스토어랩스 | Anti-obesity cream composition containing fucoxanthin |
| KR20140103488A (en) * | 2013-02-18 | 2014-08-27 | 정읍시 | Fermented green tea using microorganism and method for preparing the same |
| EP2813207A1 (en) | 2013-05-24 | 2014-12-17 | Roberto Bianco | Anti-cellulite product based on natural essences |
| JP2020036561A (en) * | 2018-09-05 | 2020-03-12 | 株式会社 伊藤園 | Green tea composition for inhibition of reduction of cognitive function associated with workload |
| WO2020096299A1 (en) * | 2018-11-05 | 2020-05-14 | (주)아모레퍼시픽 | Green tea extract having modified constituent content and composition comprising same |
Non-Patent Citations (5)
| Title |
|---|
| CHACKO SABU M ET AL: "Beneficial effects of green tea: A literature review", CHINESE MEDICINE, BIOMED CENTRAL LTD, LO, vol. 5, no. 1, 6 April 2010 (2010-04-06), pages 13, XP021081684, ISSN: 1749-8546, DOI: 10.1186/1749-8546-5-13 * |
| DATABASE GNPD [online] MINTEL; 1 November 2019 (2019-11-01), ANONYMOUS: "Firming + Detox Body Concentrate", XP055905655, retrieved from https://www.gnpd.com/sinatra/recordpage/6997669/ Database accession no. 6997669 * |
| DATABASE GNPD [online] MINTEL; 12 January 2018 (2018-01-12), ANONYMOUS: "No 1 Make-Up Remover Balm Coconut Oil + Matcha", XP055905656, retrieved from https://www.gnpd.com/sinatra/recordpage/5352199/ Database accession no. 5352199 * |
| LING-LING: "Tea Polysaccharides and Their Bioactivities", 30 October 2016 (2016-10-30), XP055905673, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274327/pdf/molecules-21-01449.pdf> [retrieved on 20220328] * |
| PRIPDEEVECH PATCHAREE ET AL: "Analysis of Volatile Constituents of Fermented Tea with Bacillus subtilis by SPME-GC-MS", CHIANG MAI J. SCI, 1 January 2014 (2014-01-01), XP055904855, Retrieved from the Internet <URL:https://www.thaiscience.info/Journals/Article/CMJS/10932728.pdf> [retrieved on 20220324] * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1555999B1 (en) | Cosmetical use of kombucha for treating skin aging | |
| EP0892642B1 (en) | Use in a composition of an extract of at least one labiate of the genus rosmarinarus, cultured in vitro | |
| EP3060228B1 (en) | Lipid extract of passion fruit seeds | |
| EP1648569B1 (en) | Cosmetic use of a composition containing at least one oxazoline, serving as an active substance, as a slimming product and/or for preventing and/or treating cellulite | |
| FR2799369A1 (en) | COMBINATION OF ESCINE AND DEXTRAN SULFATE AND THE USE THEREOF | |
| EP0655235B1 (en) | Slimming composition | |
| FR2808191A1 (en) | PLANT EXTRACT FROM THE OLEA EUROPAEA SPECIES AS A NO-SYNTHASE INHIBITOR AND USES | |
| WO1999007397A1 (en) | Use of polygonatum extracts for stimulating dermal elastin synthesis | |
| WO2004002435A2 (en) | Use of isoflavones for promoting slimming | |
| EP2026879B1 (en) | Use of peptides as active slimming ingredients | |
| EP1722757B1 (en) | Slimming cosmetic composition comprising a metalloproteinase inhibitor as an active agent | |
| FR2862533A1 (en) | Topically applied slimming agent, useful e.g. for combating cellulite or orange-peel skin, containing activator of cellular interleukin 11 production, preferably hydroxy-stilbene derivative | |
| EP0907353A1 (en) | Slimming cosmetic composition containing a chrysanthellum indicum extract | |
| FR3126870A1 (en) | Pharmaceutical or cosmetic composition intended to improve cellulite and varicose veins, characterized in that it comprises a combination of theanine and polysaccharides derived from matcha. | |
| FR2880278A1 (en) | Use of oil or proteins extracted from Plukenetia volubilis seed as an active ingredient in the preparation of cosmetic composition or dermatological product e.g. as skin and hair care product | |
| CA2467734A1 (en) | Composition based on diosgenin ester for topical use | |
| FR2913602A1 (en) | Composition, useful e.g. for care of skin damaged by aesthetic treatment, cosmetic/therapeutic such as surgical interventions, laser treatment, dermabrasions and peelings, comprises peptide associated with oil having alpha-linolenic acid | |
| FR3005408A1 (en) | USE OF PETROSELINIC ACID TO COMBAT THE AESTHETIC DISORDERS OF SILHOUETTE ASSOCIATED WITH MODIFICATIONS OF ADIPOSE TISSUE | |
| FR3004347A1 (en) | COSMETIC COMPOSITION COMPRISING ESSENTIAL OIL OF SAGE AND USE THEREOF | |
| EP0872244A1 (en) | Cosmetic or pharmaceutical composition containing an Andiroba extract | |
| WO2015036704A1 (en) | Cosmetic or dermatological use of an extract of tapirira guianensis | |
| EP3849668B1 (en) | Use of plant extracts in cosmetics | |
| FR2885301A1 (en) | Cosmetic or dermatological composition, useful to reduce and/or control skin redness, comprises active ingredients of polyphenols of vegetable extracts of green tea and/or soya in association with vegetable extracts of Ginkgo biloba leaves | |
| FR2967063A1 (en) | Non-therapeutic cosmetic use of at least one pomegranate extract, as agent for firming skin of a subject, who has weight modification prior to and/or after an aesthetic surgery and to prevent and/or treat sagging skin | |
| FR2871381A1 (en) | Topical cosmetic/dermatological composition, useful e.g. to fight against signs of cutaneous ageing, comprises an marsh mallow extract (Althea officinalis) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 2 |
|
| PLSC | Publication of the preliminary search report |
Effective date: 20230317 |
|
| PLFP | Fee payment |
Year of fee payment: 3 |